上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2015 THIRD QUARTERLY REPORT

[illegible] 13.09(2) [illegible] 13.10B [illegible] (C[illegible] 571 [illegible]).

[illegible] 2015 [illegible] (G[illegible]) C[illegible] L[illegible].* ([illegible] "**Company**", [illegible] "**Group**"). [illegible]

B[illegible]
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

[illegible]
29 [illegible] 2015

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* *for identification purposes only*

1. IMPORTANT NOTICE

1.1 (the "**Board**") (the "**Supervisory Committee**")

1.2

1.3

1.4

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 M[illegible]

[illegible] C[illegible] : MB

	As at the end of the Reporting Period (30 September 2015)	As at the end of the previous year (31 December 2014)	Change recorded at the end of the Reporting Period

E [illegible]

[illegible] C[illegible]: MB

Items	Amounts during the Reporting Period (Jul – Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan – Sep 2014)	Description
[illegible]	97,665,175.84	191,310,773.56	M[illegible]
G[illegible] ([illegible] C[illegible])	7,521,005.13	20,952,587.13	
G[illegible] C[illegible]			
[illegible]	90,352,768.11	617,479,614.88	M[illegible] G[illegible]
N[illegible]	–710,975.01	–4,388,950.98	
[illegible]	98,487.91	–16,101,512.09	
E[illegible]	–48,001,772.19	–202,411,118.11	
I[illegible] ([illegible])	14,245,629.96	–24,635,526.51	
[illegible]	161,170,319.75	582,205,867.88	

2.2 , 10 10 C

73,142						
The shareholding status of the Top 10 shareholders						
Name of shareholders (full name)	**Shareholding at the end of the period**	**Percentage (%)**	**Number of restricted shares held**	**Shares pledged or locked up**		**Capacity**
				Status	**Number**	
HANGHAI F N HIGH ECHN L G (G) C M AN LIMI ED (“F G ”)	920,641,314	39.83	0	N	0	D
HK CC N MINEE LIMI ED (N 1)	402,619,300	17.42	0		0	
CHINA EC I IE FINANCE C A I N LIMI ED	69,112,399	2.99	0	N	0	
NA I NAL CIAL EC I F ND 104 F LI *	37,199,998	1.61	0	N	0	
H NG K NG EC I IE CLEA ING C M AN LIMI ED (N 2)	33,556,005	1.45	0	N	0	
CEN AL H IJIN IN E MEN L D.	24,067,700	1.04	0	N	0	
INH A LIFE IN ANCE C ., L D. — DI IDEND — G DI IDEND — 018L — FH001 HANGHAI*	22,652,864	0.98	0	N	0	
ING CA I AL (BEIJING) C ., L D — ING CA I AL G H F ND N . I*	17,695,247	0.77	0	N	0	
F IC ING ELEC ED 1*	16,764,537	0.73	0	N	0	
ING AN C , L D — ELI E IN E MEN • ING CA I AL	16,567,783	0.72	0	N	0	

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
F[illegible] G[illegible]	920,641,314	MB[illegible]	920,641,314
HK CC N●MINEE LIMI ED *(Note 1)*	402,619,300	[illegible]	402,619,300
CHINA EC I IE FINANCE C● ● A I●N LIMI ED	69,112,399	MB[illegible]	69,112,399
NA I●NAL ●CIAL EC I F ND 104 ● F●LI●*	37,199,998	MB[illegible]	37,199,998
H●NG K●NG EC I IE CLEA ING C●M AN LIMI ED *(Note 2)*	33,556,005	MB[illegible]	33,556,005
CEN AL H IJIN IN E MEN L D.	24,067,700	MB[illegible]	24,067,700
[illegible]INH A LIFE IN ANCE C●., L D. — DI IDEND — G ● DI IDEND — 018L — FH001 HANGHAI*	22,652,864	MB[illegible]	22,652,864
ING CA I AL (BEIJING) C●., L D — ING CA I AL G ● H F ND N●. I*	17,695,247	MB[illegible]	17,695,247
F● IC ING ELEC ED 1*	16,764,537	MB[illegible]	16,764,537
ING AN C●., L D — ELI E IN E MEN • ING CA I AL	16,567,783	MB[illegible]	16,567,783
D[illegible]	ING CA I AL (BEIJING) C●., L D — ING CA I AL G ● H F ND N●. I*, F● IC ING ELEC ED 1* ING AN C●., L D — ELI E IN E MEN • ING CA I AL ING CA I AL (BEIJING) C●., L D. [illegible]		
D[illegible]	N[illegible]		

Note 1: HK CC N●MINEE LIMI ED, [illegible] H[illegible] K[illegible] C[illegible] C[illegible] N[illegible] L[illegible]

Note 2: H●NG K●NG EC I IE CLEA ING C●M AN LIMI ED [illegible] MB[illegible] -H[illegible] K[illegible] C[illegible].

2.3 [illegible] 10 [illegible] 10 [illegible] C[illegible]

N[illegible]

3. SIGNIFICANT EVENTS

3.1 [illegible]

[illegible] MB

Balance Sheet				
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons
[illegible]	485,549,599.95	198,755,576.52	144.29%	[illegible]
[illegible]		990,340,787.62	–100.00%	[illegible]
[illegible]	3,494,730.03	11,246,964.92	–68.93%	[illegible]
[illegible]	3,529,897,004.62	2,499,156,438.67	41.24%	[illegible]
[illegible]	167,214,321.23	89,379,481.02	87.08%	[illegible]
[illegible]	4,508,065,870.77	2,841,223,392.47	58.67%	[illegible]
[illegible]	474,418,367.92	342,926,461.15	38.34%	[illegible]
[illegible]	14,831,357.70	1,279,819.25	1,058.86%	[illegible]
[illegible]		589,118,424.34	–100.00%	[illegible]
[illegible]	2,822,255,623.13	1,109,525,523.85	154.37%	[illegible]
[illegible]	63,116,411.43	1,070,561,681.96	–94.10%	[illegible]
[illegible]	1,618,247,844.35	771,191,646.56	109.84%	[illegible]
[illegible]	1,894,480,886.28	3,085,482,735.30	–38.60%	[illegible]

Income Statement				
Items	Current amount Jan – Sep 2015	Amount of the last period Jan – Sep 2014	Ratio of change	Reasons
[illegible]	339,686,256.62	251,024,209.33	35.32%	[illegible]
[illegible]	33,340,027.70	11,784,007.60	182.93%	[illegible]
[illegible]	3,506,487.53	–9,516,778.44	136.85%	[illegible]
[illegible]	63,499,502.52	38,512,060.43	64.88%	[illegible]
[illegible]	10,862,409.73	15,531,263.99	–30.06%	[illegible]
[illegible]	–279,141,519.38	146,057,212.28	–291.12%	[illegible]

Statement of Cash Flow				
Items	Current amount Jan – Sep 2015	Amount of the last period Jan – Sep 2014	Ratio of change	Reasons
[illegible]	1,161,951,526.99	843,637,595.71	37.73%	[illegible]
[illegible]	764,402,303.12	1,793,987,740.16	–57.39%	[illegible] 2014 [illegible]

Note: I 2014, [illegible] C [illegible] 31 D [illegible] 2014, [illegible] F [illegible] C [illegible] L [illegible] * (上海□星藥業有限公司) ([illegible] H [illegible] G D F M [illegible] C [illegible] L [illegible] * (國藥控股國大□美藥業(上海)有限公司)), [illegible] F M [illegible] C [illegible] L [illegible] * (上海□美益星大藥房連鎖有限公司) ([illegible] H [illegible] G D F M [illegible] C [illegible] L [illegible] * (國藥控股國大□美大藥房上海連鎖有限公司)) [illegible] B [illegible] G [illegible] E [illegible] M [illegible] C [illegible] L [illegible] * (北京金象大藥房醫藥連鎖有限責任公司) [illegible] D [illegible] “A [illegible]” “[illegible]” [illegible].

3.2 A

(1) ● 20 J 2015, 41 B ( ) C 2015 ( ). C A I, II ( ). C 2,719,000 A C MB10.82 47 . ● 4 M 2015, C " F (G) C ., L .* A I " (B H 2015[N . 215) (《關於上海□星醫藥(集團)股份有限公司股權激勵計劃意見的函》(上市部函 2015[215號)) O C ("C C") C A I II.

● 25 A 2015, 54 B ( ) C 2015 ( ). C A I II ( ). C A I II 47 46 C , M . L A 2,719,000 2,704,000 A I II C A H C .

(2) I C 2013 C . ● 3 A 2015, C "N A, (. 2015[N . M N 65) (《接受註冊通知書》(中市協註 2015[M N65號)) N A F M I I ("A "). A C . C MB2 , I C B O L E -I B O .

● 10 2015, C 2015 MB400 C 10 2015.

(3) 16 A 2015, 46

B ( )

C 2015 ( )

A

C 246,808,510 A MB23.50

* (中國人壽保險股份有限公司),

M A M C., L.* (招商財富資產管理有限公司),

A M C., L.* (泰康資產管理有限責任公司),

M C., L.* (中信建投基金管理有限公司),

A M

C L * (匯添富基金管理股份有限公司), A C

F C., L.* (安□省鐵路建設投資基金有限公司), B D

M C., L.* (北京中融鼎新投資管理有限公司) E G C.,

L.* (億利資源控股有限公司). C A

G MB5,799,999,985

A

MB3,600,000,000

2014

C 21 A 2015,

MB23.22

249,784,664 A

16 2015, 56

B ( )

C 2015 ( ) C

A C

C A

A

A A

211,024,978

MB4,899,999,989.16.

A C

C C.

(4) 27 A 2015, 55

B ( ) C

C MB5

7

C

3.3 [illegible] 5% [illegible]

Background	Type	Covenantors	Undertakings	Validity period	Whether duration specified	Whether timely and strictly performed
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]		
[illegible]	[illegible]	[illegible]	[illegible] (Note 1) [illegible]	[illegible] (Note 2) [illegible]		

Note 1: [illegible] 622 [illegible]

Note 2: [illegible] 13 [illegible] 2012.

3.4 [illegible]

[illegible]

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

[illegible]: **Chen Qiyu**

29 [illegible] 2015

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2015

[illegible]: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.**

[illegible] C[illegible] : MB [illegible]

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C[illegible]	3,516,813,404.78	3,695,698,185.82
[illegible]		
L[illegible]		
E[illegible]	38,724,495.54	33,770,584.14
B[illegible]	408,527,911.80	472,523,132.71
[illegible]	1,789,464,377.02	1,504,149,790.72
[illegible]	136,605,468.61	137,690,114.05
[illegible]		
[illegible]		
[illegible]		
I[illegible]	677,257.70	1,023,889.42
D[illegible]	16,983,973.47	14,264,402.96
[illegible]	485,549,599.95	198,755,576.52
[illegible]		
I[illegible]	1,627,321,198.79	1,604,562,390.25
A[illegible]		990,340,787.62
N[illegible]		
[illegible]	3,494,730.03	11,246,964.92
[illegible]	8,024,162,417.69	8,664,025,819.13
Non-current assets:		
[illegible]		
A[illegible]	3,529,897,004.62	2,499,156,438.67
H[illegible]		
L[illegible]		
L[illegible]	13,489,435,775.47	11,905,750,117.54
I[illegible]		
F[illegible]	4,720,292,409.25	4,623,958,317.63
C[illegible]	964,172,888.14	1,051,988,109.53
[illegible]	3,233,982.94	5,450,698.63
D[illegible]		
[illegible]		
[illegible]		
I[illegible]	2,857,317,020.41	2,822,483,093.20
D[illegible]	167,214,321.23	89,379,481.02
G[illegible]	3,292,538,591.11	3,255,041,739.55
L[illegible]	11,804,369.09	13,583,440.85
D	92,366,614.48	101,221,671.79
[illegible]	262,125,551.28	304,238,328.42
[illegible]	29,390,398,528.02	26,672,251,436.83
[illegible]	37,414,560,945.71	35,336,277,255.96

Consolidated balance sheet *(Continued)*

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
[illegible]	4,508,065,870.77	2,841,223,392.47
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]	67,928,606.53	70,987,451.05
[illegible]	874,465,599.33	833,974,948.21
[illegible]	226,002,022.22	266,518,255.34
[illegible]		
[illegible]		
[illegible]	296,895,628.48	298,472,746.11
[illegible]	474,418,367.92	342,926,461.15
[illegible]	166,803,873.32	177,075,081.31
[illegible]	14,831,357.70	1,279,819.25
[illegible]	1,379,103,280.44	1,935,656,885.83
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		589,118,424.34
[illegible]	2,822,255,623.13	1,109,525,523.85
[illegible]	63,116,411.43	1,070,561,681.96
[illegible]	10,893,886,641.27	9,537,320,670.87
Non-current liabilities:		
[illegible]	1,618,247,844.35	771,191,646.56
[illegible]	1,894,480,886.28	3,085,482,735.30
[illegible]	890,883,419.71	710,056,624.65
[illegible]		
[illegible]		
[illegible]	178,123,561.73	139,593,190.51
[illegible]	1,934,427,964.42	1,929,331,107.42
[illegible]	73,391,869.13	60,299,392.99
[illegible]	6,589,555,545.62	6,695,954,697.43
[illegible]	17,483,442,186.89	16,233,275,368.30
Equity:		
[illegible]	2,311,380,364.00	2,311,611,364.00
[illegible]	6,049,708,237.59	6,123,454,191.14
[illegible]		
[illegible]		
[illegible]	838,468,407.81	1,120,365,125.73
[illegible]	1,662,373,054.64	1,662,373,054.64
[illegible]		
[illegible]	6,700,890,376.05	5,457,045,050.64
[illegible]		
[illegible]	17,562,820,440.09	16,674,848,786.15
[illegible]	2,368,298,318.73	2,428,153,101.51
[illegible]	19,931,118,758.82	19,103,001,887.66
[illegible]	37,414,560,945.71	35,336,277,255.96

Legal Representative: **Chen Qiyu**

Chief Financial Officer: **Guan Xiaohui**

Director of the Accounting Department: **Yan Jia**

Balance Sheet of the Parent Company *(Continued)*

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
[illegible]	1,834,226,000.00	
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]	78,632,661.11	72,568,579.44
[illegible]	23,932,653.33	21,842,286.49
[illegible]	147,159,729.00	160,716,398.26
[illegible]	1,364,923.50	1,062,450.00
[illegible]	453,068,674.16	587,606,051.26
[illegible]	2,641,935,028.99	1,037,216,423.85
[illegible]		998,894,520.55
[illegible]	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
[illegible]	186,740,000.00	85,000,000.00
[illegible]	1,894,480,886.28	3,085,482,735.30
[illegible]		
[illegible]		
[illegible]		
[illegible]	1,525,000.00	1,750,000.00
[illegible]	1,209,260,573.79	1,192,857,263.79
[illegible]		
[illegible]	3,292,006,460.07	4,365,089,999.09
[illegible]	8,472,326,130.16	7,244,996,708.94
Equity:		
[illegible]	2,311,380,364.00	2,311,611,364.00
[illegible]	8,227,835,906.44	8,270,816,715.22
[illegible]		
[illegible]		
[illegible]	55,747,958.04	224,689,817.57
[illegible]	949,985,460.52	949,985,460.52
[illegible]		
[illegible]	4,193,926,575.18	2,839,595,396.66
[illegible]	15,738,876,264.18	14,596,698,753.97
[illegible]	24,211,202,394.34	21,841,695,462.91

Legal Representative: **Chen Qiyu** *Chief Financial Officer:* **Guan Xiaohui** *Director of the Accounting Department:* **Yan Jia**

Consolidated Income Statement

January – September 2015

: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.**

C : MB

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I.	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I :	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I				
E				
F				
II.	2,895,782,154.22	2,841,148,358.80	8,300,064,068.03	8,033,810,333.58
I :	1,549,543,653.59	1,718,871,717.37	4,479,008,803.33	4,905,488,021.73
I				
F				
C				
N				
A				
B	24,497,548.36	23,567,831.20	74,510,036.45	59,883,149.42
	752,785,285.93	589,494,712.71	2,033,469,048.98	1,606,792,320.56
A	439,321,906.97	417,425,034.77	1,340,049,894.95	1,198,838,624.94
F	118,030,107.88	91,347,934.22	339,686,256.62	251,024,209.33
A	11,603,651.49	441,128.53	33,340,027.70	11,784,007.60
: G				

Consolidated Income Statement *(Continued)*

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I. [illegible]	–503,674,636.21	170,383,244.67	–279,141,519.38	146,057,212.28
[illegible]	–506,044,279.16	169,738,571.45	–281,896,717.92	147,808,244.36
(i) [illegible]				
1. [illegible]				
2. [illegible]				
(ii) [illegible]	–506,044,279.16	169,738,571.45	–281,896,717.92	147,808,244.36
1. [illegible]	732,427.55	–9,352.18	–195,739,333.69	–5,108,705.95
2. [illegible]	–440,970,255.91	171,599,596.74	–16,216,735.14	149,088,050.35
3. [illegible]				
4. [illegible]				
5. [illegible]	–65,806,450.80	–1,851,673.11	–69,940,649.09	3,828,899.96
6. [illegible]				
[illegible]	2,369,642.95	644,673.22	2,755,198.54	–1,751,032.08
II. [illegible]	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
[illegible]	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
[illegible]	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
III. [illegible]:				
(1) [illegible]	0.25	0.24	0.82	0.69
(2) [illegible]	0.25	0.24	0.82	0.69

Legal Representative: **Chen Qiyu** *Chief Financial Officer:* **Guan Xiaohui** *Director of the Accounting Department:* **Yan Jia**

Consolidated Statement of Cash Flow

January – September 2015

[illegible]: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.**

[illegible] MB [illegible]

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
I. Cash flow generated from operating activities:		
[illegible]	11,787,872,270.19	10,459,786,860.15
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]	30,317,198.52	72,648,588.55
[illegible]	97,662,080.84	94,521,561.68
[illegible]	11,915,851,549.55	10,626,957,010.38
[illegible]	6,127,603,506.07	6,154,725,576.22
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]		
[illegible]	1,406,092,878.78	1,216,716,910.44
[illegible]	1,055,403,620.12	851,073,785.17
[illegible]	2,164,800,017.59	1,560,803,142.84
[illegible]	10,753,900,022.56	9,783,319,414.67
[illegible]	1,161,951,526.99	843,637,595.71
II. Cash flow generated from investing activities:		
[illegible]	856,889,234.08	1,024,268,371.05
[illegible]	100,352,896.71	88,024,272.04
[illegible]	9,861,620.38	90,869,547.68
[illegible]	315,852,788.57	48,736,636.59
[illegible]	107,075,600.48	439,566,546.01
[illegible]	1,390,032,140.22	1,691,465,373.37
[illegible]	738,403,167.55	855,603,820.63
[illegible]	2,327,525,471.23	1,732,041,861.35
[illegible]		
[illegible]	45,071,121.94	628,770,325.12
[illegible]	182,668,212.99	246,994,986.24
[illegible]	3,293,667,973.71	3,463,410,993.34
[illegible]	–1,903,635,833.49	–1,771,945,619.97

Consolidated Statement of Cash Flow *(Continued)*

January – September 2015

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III. Cash flow generated from financing activities:		
[illegible]	87,721,195.00	1,445,949,451.00
[illegible]	87,721,195.00	38,269,850.07
[illegible]	5,110,056,682.54	3,475,109,758.30
[illegible]	398,929,000.00	1,000,000,000.00
[illegible]	40,140,014.05	21,733,509.09
[illegible]	5,636,846,891.59	5,942,792,718.39
[illegible]	3,519,139,442.58	1,623,242,732.68
[illegible]	1,114,614,719.91	1,012,768,967.52
[illegible]	268,686,768.21	133,554,721.22
[illegible]	238,690,425.98	1,512,793,278.03
[illegible]	4,872,444,588.47	4,148,804,978.23
[illegible]	764,402,303.12	1,793,987,740.16
IV. Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V. Net increase of cash and cash equivalents	[illegible]	[illegible]

Statement of Cash Flow of the Parent Company

January – September 2015

[illegible]: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.**

[illegible]: [illegible] C [illegible]: MB [illegible]

	Items	Current Amount (January – September)	Amount of the Last Period (January – September)
I.	**Cash flow generated from operating activities:**		
	[illegible]	450,000.00	450,000.00
	[illegible]		
	[illegible]	17,027,016.02	24,262,470.46
	[illegible]	17,477,016.02	24,712,470.46
	[illegible]		
	[illegible]	76,034,052.14	55,675,865.31
	[illegible]	34,051,409.56	38,638,399.47
	[illegible]	46,784,926.39	28,772,270.22
	[illegible]	156,870,388.09	123,086,535.00
	[illegible]	–139,393,372.07	–98,374,064.54
II.	**Cash flow generated from investing activities:**		
	[illegible]	246,952,337.32	
	[illegible]	341,508,734.72	135,001,207.03
	[illegible]		150,000.00
	[illegible]		10,351,169.50
	[illegible]		408,839,600.00
	[illegible]	588,461,072.04	554,341,976.53
	[illegible]	1,023,410.77	3,334,618.53
	[illegible]	1,286,782,424.70	1,780,579,380.37
	[illegible]		27,023,100.00
	[illegible]		20,000,000.00
	[illegible]	1,287,805,835.47	1,830,937,098.90
	[illegible]	–699,344,763.43	–1,276,595,122.37
III.	**Cash flow generated from financing activities:**		
	[illegible]		1,407,679,600.93
	[illegible]	2,281,014,000.00	850,000,000.00
	[illegible]	398,929,000.00	1,000,000,000.00
	[illegible]	4,785,211,767.92	4,754,495,093.76
	[illegible]	7,465,154,767.92	8,012,174,694.69
	[illegible]	1,345,000,000.00	601,000,000.00
	[illegible]	880,988,031.73	829,585,897.32
	[illegible]	4,263,390,819.81	4,365,392,837.67
	[illegible]	6,489,378,851.54	5,795,978,734.99
	[illegible]	975,775,916.38	2,216,195,959.70
IV.	**Effects of exchange rate fluctuations on cash and cash equivalents**	–4,232,440.84	9,803,068.68
V.	**Net increase of cash and cash equivalents**	132,805,340.04	851,029,841.47
	[illegible]	506,943,460.86	519,292,385.71
VI.	**Closing balance of cash and cash equivalents**	639,748,800.90	1,370,322,227.18

Legal Representative:	*Chief Financial Officer:*	*Director of the Accounting Department:*
Chen Qiyu	**Guan Xiaohui**	**Yan Jia**

4.2 Audited Report

N [illegible]